Staphylococcal Infection Clinical Trial
Official title:
A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA
The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02899702 -
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
|
Phase 4 | |
Completed |
NCT00352612 -
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
|
Phase 4 | |
Completed |
NCT00279864 -
The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection
|
N/A | |
Completed |
NCT00735839 -
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
|
Phase 1 | |
Completed |
NCT00814151 -
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
|
N/A | |
Completed |
NCT02812446 -
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
|
N/A | |
Completed |
NCT00846105 -
Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)
|
N/A | |
Completed |
NCT02284555 -
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
|
Phase 4 | |
Completed |
NCT01592214 -
Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
|
Phase 1 | |
Completed |
NCT01827358 -
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
|
Phase 2 | |
Completed |
NCT00729937 -
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
|
Phase 2/Phase 3 | |
Completed |
NCT00730028 -
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
|
Phase 2 |